for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Livzon Pharmaceutical Group Inc.

000513.SZ

Latest Trade

36.82CNY

Change

-1.44(-3.76%)

Volume

9,329,495

Today's Range

36.82

 - 

38.05

52 Week Range

34.00

 - 

57.50

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
38.26
Open
37.96
Volume
9,329,495
3M AVG Volume
159.87
Today's High
38.05
Today's Low
36.82
52 Week High
57.50
52 Week Low
34.00
Shares Out (MIL)
937.87
Market Cap (MIL)
30,396.17
Forward P/E
17.90
Dividend (Yield %)
3.39

Next Event

Q4 2021 Livzon Pharmaceutical Group Inc Earnings Release

Latest Developments

更多

Livzon Pharma Expects Net Profit To Rise Up To 10% Y/Y In 2021

Livzon Pharmaceutical Made A Total Repurchase Of 2.7 Million H Shares Of Co As At 6 Dec

Livzon Pharma's Covid-19 Vaccine Candidate Gets Approval To Conduct Phase III Clinical Trial In Pakistan

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Livzon Pharmaceutical Group Inc.

LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs, Chinese medicine preparation, active pharmaceutical ingredient and intermediates, diagnostic reagents and equipments. The Company distributes its products in the domestic market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

Livzon Mansion

No.132, Guihua Road North, Gongbei

ZHUHAI, GNG

519090

China

+86.756.8135888

http://www.livzon.com.cn

Executive Leadership

Baoguo Zhu

Chairman of the Board, Non-Executive Director

Yanggang Tang

President, Executive Director

Guoxiang Xu

Vice Chairman of the Board, Vice President, Executive Director

Desheng Tao

Vice Chairman of the Board, Non-Executive Director

Yanxia Si

Finance Director, Vice President

Key Stats

2.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

8.9K

2019

9.4K

2020

10.5K

2021(E)

11.9K
EPS (CNY)

2018

1.162

2019

1.390

2020

1.830

2021(E)

2.057
Price To Earnings (TTM)
19.90
Price To Sales (TTM)
2.54
Price To Book (MRQ)
2.75
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
28.15
LT Debt To Equity (MRQ)
5.14
Return on Investment (TTM)
14.94
Return on Equity (TTM)
9.35

Latest News

Latest News

UPDATE 1-China Livzon Pharma affiliate's COVID-19 vaccine candidate enters phase III trial

A potential COVID-19 vaccine developed by a biotech firm affiliated with China's Livzon Pharmaceutical Group Inc (Livzon) has entered a late-stage trial, Livzon said late on Thursday.

China Livzon Pharma affiliate's COVID-19 vaccine candidate enters phase III trial

A potential COVID-19 vaccine developed by a biotech firm affiliated with China's Livzon Pharmaceutical Group Inc (Livzon) has entered a late-stage trial, Livzon said in a filing late on Thursday.

Livzon's COVID-19 vaccine appears safe, triggers antibodies -study

A potential COVID-19 vaccine developed by a subsidiary of China's Livzon Pharmaceutical Group Inc appeared safe and able to elicit antibodies in healthy adults in a mid-stage clinical trial, Chinese researchers said.

UPDATE 1-China approves clinical trials for Livzon Pharma unit's COVID-19 vaccine

China's medical products regulator has approved clinical trials for a COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc, the Chinese company said late on Tuesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up